linjc16/ctgov huggingface dataset:
OCTA Study of Choroidal Vasculature in Open Angle Glaucoma Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the present study was to examine and measure SFCT and CCVD using respectively EDI-OCT and OCTA in preperimetric and advanced glaucomatous eyes, in order to shed light on the vascular pathogenesis of glaucoma disease.

Official Title
-----------------
OCTA as a New Biomarker in the Pathogenesis of Primary Open Angle Glaucoma

Conditions
-----------------
Glaucoma Open-Angle Primary

Intervention / Treatment
-----------------
* Diagnostic Test: OCTA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:• age older than 40 years diagnosis of glaucoma absence of diabetes, heart diseases, hypertension absence of drug intake absence of vitreoretinal, vascular retinal diseases absence of previous ocular surgery and congenital eye diseases. absence of errors of refraction absence of lens opacities absence of low-quality OCT and OCTA images Exclusion Criteria: age younger than 40 years presence of diabetes, heart diseases, hypertension vitreoretinal and vascular retinal diseases previous ocular surgery and congenital eye diseases errors of refraction lens opacities low-quality OCT and OCTA images

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with pre perimetric open angle glaucoma<br> | Diagnostic Test: OCTA<br>* Choriocapillary vessel density calculated with OCTA<br>|
| patients with perimetric open angle glaucoma<br> | Diagnostic Test: OCTA<br>* Choriocapillary vessel density calculated with OCTA<br>|
| healthy patients<br> | Diagnostic Test: OCTA<br>* Choriocapillary vessel density calculated with OCTA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The measurements of choroidal thickness and choriocapillary vessel density in patients with open angle glaucoma. | correlation of measurement of choroidal thickness and choriocapillary vessel density in three different patients groups | up to 5 months |
uPHI: Wireless Body Area Network Core Technology

Study Overview
=================
Brief Summary
-----------------
The application scenario is shown in the figure below: the user utilizes an ECG-based wireless sensor (WiBoC Chipset), and transmit those signals to a mobile-phone device that has an embedded expert system integrated. With the aid of 3G system, a remote healthcare monitoring center receives those uploaded signals and stores into the application server. According to the events from this server, the people on service responses to the emergency and takes the corresponding process.

Official Title
-----------------
uPHI: Wireless Body Area Network Core Technology

Conditions
-----------------
Asystole, Sinus Bradycardia, Sinus Tachycardia, Sinus Arrhythmia, Atril Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency patient with chest pain. Emergency patients were implementation of 12-lead EKG during observation. Out-patient services of Cardiology with arrhythmia history. Adults over 20 years old. Exclusion Criteria: The patient required the intervention of resuscitation and cardiac massage. Chest trauma On pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention

Study Overview
=================
Brief Summary
-----------------
This randomized open-label study will be comprised of 2 cohorts: one control group and one treatment group. The trial will be conducted as an open label randomized trial to evaluate the efficacy of tamsulosin in the prevention of post-operative urinary retention. The study will include pre- and post-surgical evaluations of patients including symptoms of urinary retention and any adverse effects contributable to the study medication.

Official Title
-----------------
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention

Conditions
-----------------
Post-Operative Urinary Retention

Intervention / Treatment
-----------------
* Drug: Tamsulosin
* Other: Education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any male age 40 or older Scheduled to undergo one of the planned surgeries (thoracic, general, or urologic) Ability to give informed consent Exclusion Criteria: Current use of alpha blocker Current use of a strong CYP 3A4 inhibitors Any allergy to tamsulosin, alpha-blocker medication class, or anaphylaxis allergy to sulfate containing medications Patients with any upcoming surgery for cataracts Currently enrolled in a clinical trial Inability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tamsulosin Group<br>Subjects will receive: 0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery education about signs and symptoms of urinary retention | Drug: Tamsulosin<br>* Tamsulosin may have prophylactic properties against post-operative urinary retention<br>* Other names: Flomax;Other: Education<br>* Education about signs and symptoms of urinary retention<br>|
| Active Comparator: Education Group<br>Subjects will receive: 1) education about signs and symptoms of urinary retention | Other: Education<br>* Education about signs and symptoms of urinary retention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Post-operative Urinary Retention |  | 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post-Operative Urinary Retention
Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Study Overview
=================
Brief Summary
-----------------
The primary objective of the proposed project is to estimate the economic impact of a national rotavirus immunization program in preventing rotavirus diarrhea among Korean children.

Detailed Description
-----------------
Rotavirus is the leading cause of severe acute diarrhea or gastroenteritis among young children worldwide. In the first 5 years of life, about 90% of children experience at least one episode of rotavirus infection.Each year, rotavirus diarrhea is responsible for 440,000 deaths, 2 million hospitalizations, and 25 million outpatient visits among children younger than 5 years worldwide. In South Korea, rotavirus diarrhea rarely causes mortality, but it cause significant morbidity. A recent population-based study in Korea has estimated that the annual incidence of rotavirus diarrhea accounts for 56.9 cases per 1,000 children less than 5 years old. Oral, live pentavalent human-bovine reassortant rotavirus vaccine has been developed and licensed for the use of preventing rotavirus disease in many countries. Yet, there has been no research done to assess the impact of national rotavirus immunization program in Korea. It is expected that systematic appraisal on the national burden of rotavirus infection and potential public health and economic benefits of rotavirus vaccination for children in Korea will assists health policy makers to set a priority for the prevention of this disease.

Official Title
-----------------
Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Conditions
-----------------
Gastroenteritis, Rotavirus Vaccines, Cost-Effectiveness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children aged under 5 years and diagnosed as acute gastroenteritis Exclusion Criteria: none

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>patients visited to Severance hospital | |
| 2<br>patients visited to Youngdong Severance hospital | |
| 3<br>patients visited to Wonju Christian hospital | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients' cost |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cost effectiveness analysis of rotavirus vaccination
Rheumatology Informatics System for Effectiveness

Study Overview
=================
Brief Summary
-----------------
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR) and allows for a simplified entry process, while establishing a best-in-class resource to manage your patient population and improve patient care. RISE provides participants with an infrastructure for robust quality improvement activities leading to improved patient outcomes, patient population management and quality reporting related to rheumatic diseases and drug safety. RISE gives physicians and researchers the information they need to optimize patient outcomes, meet reporting requirements, and make discoveries that advance rheumatology.

Detailed Description
-----------------
RISE helps providers benchmark performances on key rheumatology clinical quality measures and align with best practice standards. The RISE benchmarking tool allows providers to view the details of their patient population against established rheumatology quality metrics. RISE allows access to aggregate data from other participating sites so providers can view their patient population in comparison to other RISE participants. RISE is integrated into an electronic health records (EHR) system, bringing a single point of entry into one solution for filing for quality-based incentive payments, avoiding penalties, complying with reporting requirements and tracking caseloads for quality monitoring and improvement initiatives. RISE collects the data needed to meet current federal reporting requirements. Participating in RISE helps push the field of rheumatology practice forward. RISE provides a source of information on patient outcomes and quality care for rheumatology leading to new discoveries, better understanding and a source of comparative effectiveness research.

Official Title
-----------------
American College of Rheumatology's Rheumatology Informatics System for Effectiveness

Conditions
-----------------
Rheumatoid Arthritis, Osteoarthritis, Gout

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years of age and older with one of the following diagnoses: rheumatoid arthritis, osteoarthritis, gout Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Controlling High Blood Pressure | Percentage of patients 18-85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (<140/90mmHg) during the measurement period. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rheumatoid, arthritis, osteoarthritis, gout
Testing of Mobile Monitoring System

Study Overview
=================
Brief Summary
-----------------
We will complete a prospective, observational study comparing the accuracy of the mobile monitoring tool on identifying SSI compared to manual review.

Official Title
-----------------
To Implement and Test the Mobile Monitoring Tool to Identify SSI (R33 Phase)

Conditions
-----------------
Orthopedic Disorder

Intervention / Treatment
-----------------
* Behavioral: Mobile Monitoring Tool


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Orthopaedic surgery patient at hospital 175 Exclusion Criteria: no access to mobile phone

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mobile monitoring group<br> | Behavioral: Mobile Monitoring Tool<br>* a text-messaged based outcomes collection system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Promis PF Short form (change in self reported capability) | PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. It is scored from 0-100, a higher score indicates better physical function | 1 day, 1 week, 2 week, 4 week, 12 weeks after surgery |
Modulation of Benzene Metabolism by Exposure to Environment

Study Overview
=================
Brief Summary
-----------------
The research is to evaluate benzene metabolism after exposure at levels that can be found in the environment, such as the higher end concentrations in the air inside cars and buses while being driven in heavy traffic and inside private and public parking garages. To do so breath, urine, and blood samples prior to, during and after being exposed to benzene as well as benzene levels and benzene metabolites present are measured.

Detailed Description
-----------------
The research is to evaluate benzene metabolism after exposure at levels that can be found in the environment, such as the higher end concentrations in the air inside cars and buses while being driven in heavy traffic and inside private and public parking garages. To do so breath, urine, and blood samples prior to, during and after being exposed to benzene as well as benzene levels and benzene metabolites present are measured. The exposures take place in the Controlled Environmental Facility operated by the Environmental and Occupational Health Sciences Institute (EOHSI). This allows us to control the exact benzene air level and to use benzene containing 13C, a stable (non-radioactive) form of carbon, one of the atoms that make up benzene. Isotopes are different forms of the same atom. Using 13C will allow us to tell the difference between the benzene and the compounds it changes to in the body that come from our experiment compared to what is present in your body from other sources. In addition to just benzene exposure on some days the subject is also be exposed to methyl tertiary butyl ether (MTBE), another component of gasoline, to take an iron supplement pill and/or to take vitamins C and E pills. How benzene is metabolized or changed in the body will be compared for these differences to better understand how the body deals with benzene.

Conditions
-----------------
Lung Diseases, Cancer

Intervention / Treatment
-----------------
* Procedure: Controlled Exposure to Environmental Contaminant


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Controlled Exposure to Environmental Contaminant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benzene, Air pollution
Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of HIP0901 Capsule

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of food on the pharmacokinetic characteristics of fenofibric acid for HIP0901 capsule.

Official Title
-----------------
Open-label, Randomized Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Fenofibric Acid for HIP0901 Capsule in Healthy Male Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers, age between 20 and 45 Informed of the investigational nature of this study and voluntarily agree to participate in this study Weight>50kg, BMI of >18kg/m2 and <27kg/m2 subject Exclusion Criteria: Acute disease within 28 days prior to start of study drug administration Use of any prescription medication within 14 days prior to Day 1 Use of any medication within 7 days prior to Day 1 Has a severe medical history of hypersensitivity to fibric acid derivative Participation in another clinical study within 30 days prior to start of study drug administration

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fasting conditions<br>Investigational product administrated under fasting condition. | Dietary Supplement: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions<br>* The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions<br>|
| Active Comparator: Fed conditions<br>Investigational product administrated 30min after starting a high-fat breakfast. | Dietary Supplement: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions<br>* The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC of Fenofibric acid |  | 0-96 hrs | 
| Cmax of Fenofibric acid |  | 0-96 hrs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fenofibric acid, HIP0901, food effect
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in cell samples from young patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: To characterize Stat3 signaling pathway activity in primary tissue samples from pediatric patients with acute myeloid leukemia to determine the percentage of samples with increased activity and to better understand the mechanisms leading to increased activity. To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3 activation to low and high doses of cytokines. To evaluate the expression levels of Stat3 protein as well as upstream and downstream regulators of Stat3 activation. To classify tissue samples according to a Stat3-activation pattern, and to correlate this result with event-free survival and overall survival in order to determine whether increased Stat3 phosphorylation at diagnosis predicts poor outcome. OUTLINE: Cryopreserved cell samples are collected for laboratory analysis, including immunoblotting, fluorescence activated cell sorting (FACS), and protein analysis.

Official Title
-----------------
Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: gene expression analysis
* Genetic: protein expression analysis
* Other: fluorescence activated cell sorting
* Other: immunologic technique
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of pediatric acute myeloid leukemia PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: gene expression analysis|nan|
|Genetic: protein expression analysis|nan|
|Other: fluorescence activated cell sorting|nan|
|Other: immunologic technique|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of the Stat3 response category (constitutive, low-dose responsive, high-dose responsive, or unresponsive) with clinical data, including event-free and overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood acute myeloid leukemia/other myeloid malignancies